GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Net Income Including Noncontrolling Interests

Alphamab Oncology (HKSE:09966) Net Income Including Noncontrolling Interests

: HK$-230.3 Mil (TTM As of Jun. 2023)
View and export this data going back to 2019. Start your Free Trial

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Alphamab Oncology's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2023 was HK$-43.6 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-230.3 Mil.

Alphamab Oncology Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Alphamab Oncology's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Premium Member Only Premium Member Only -926.63 -507.09 -504.99 -363.74 -230.34

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -177.61 -172.68 -199.24 -43.60 -186.74

Alphamab Oncology Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-230.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
HKSE:06660 HKSE:01541 HKSE:09969 HKSE:01952 HKSE:02315 HKSE:06955 HKSE:02105 HKSE:06855 HKSE:02480 HKSE:02696 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
3NK:Germany
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024
Website
https://www.alphamabonc.com
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines